Libtayo trial stopped early for efficacy

Thursday 5 August 2021


A Phase 3 trial of the checkpoint inhibitor Libtayo (cemiplimab) combined with chemotherapy for patients with advanced non-small cell lung cancer was stopped early for efficacy, the sponsors Sanofi SA and Regeneron Pharmaceuticals Inc announced on 5 August. The combination therapy was found to reduce the risk of death by 29% compared with chemotherapy alone in a trial of 466 patients with locally advanced and metastatic disease.